---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-313502"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2021-10-29T23:59:59+00:00"
generated_at: "2026-06-28T16:04:29.065381+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Inovio loses AstraZeneca-partnered cancer vaccine pact; reacquires INO-3112 rights

## Summary
- MedImmune (AstraZeneca R&D) terminated INO-3112/MEDI0457 collaboration effective Oct 28, 2021.
- Inovio reacquires all rights to INO-3112; forfeits future milestone payments and royalties.
- MedImmune continues Phase 2 HNSCC trial; final data cut-off completed, study report by end of 2022.
- Revenue from the agreement was minimal: $33k in H1 2021, $171k in 2020, $2M in 2019.
- Company states it is not substantially dependent on the terminated collaboration agreement.

## SEC filing metadata
- accession: 0001193125-21-313502
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2021-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/0001193125-21-313502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/d254133d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-313502
- JSON: https://secwatch.observer/filing/0001193125-21-313502.json
- Plain text: https://secwatch.observer/filing/0001193125-21-313502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.